Article 8.01 Other events.
November 26, 2021, Biohaven Pharmaceutical Holding Company Ltd.(the "Company") filed a prospectus supplement to its Registration Statement on Form S-3 filed with the U.S. Securities and Exchange Commission(the "Commission") (No. 333-253946) (the "Registration Statement"), under the Securities Act of 1933, as amended, with respect to the resale by the selling shareholder named therein of 29,297 common shares, no par value, of the Company that were issued by the Company to such selling shareholder as share consideration in connection with the transactions and business arrangements described therein. In connection with filing of such prospectus supplement, the Company is filing a legal opinion as Exhibit No. 5.1 to this Current Report on Form 8-K, which is incorporated by reference into the Registration Statement.
Item 9.01 Financial statements and supporting documents.
(d) Exhibits Exhibit Number Exhibit Description 5.1 Opinion of Maples & Calder. 23.1 Consent of Maples & Calder (included in Exhibit 5.1). 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL. 1
© Edgar online, source